Why Jim Cramer Thinks Merck (MRK), Pfizer (PFE), GlaxoSmithKline (GSK) Bids Are Coming After InterMune (ITMN) Deal

NEW YORK (TheStreet) -- TheStreet's Jim Cramer says Roche called its purchase of InterMune  (ITMN) a "bolt-on" acquisition.

Cramer says the $8.3 billion bid signifies that big pharmaceutical companies are thinking big even as Roche calls this a "bolt-on" acquisition. Cramer notes in the old days, "bolt on" would have meant anything less than $1 billion.

Cramer calls this deal important because so many biotech companies are losing money the way InterMune was before it had a breakthrough. His game plan is for a prospective buyer to find a biotech company in stage three, which means it is about to get FDA approval, and looks like it is a need that is unmet.

Must Watch: Jim Cramer Says Roche's "Bolt-On" Acquisition Means Big Pharma is Thinking Big

STOCKS TO BUY: TheStreet Quant Ratings has identified a handful of stocks that can potentially TRIPLE in the next 12 months. Learn more.

Cramer believes bids are coming from Merck  (MRK) , Pfizer  (PFE) and GlaxoSmithKline  (GSK) because they need to do bolt-on acquisitions for growth.

ITMN Chart ITMN data by YCharts

EXCLUSIVE OFFER: See inside Jim Cramer's multi-million dollar charitable trust portfolio to see the stocks he and Stephanie Link think could be potentially HUGE winners. Click here to see the holdings for FREE.

Editor's Note: Any reference to TheStreet Ratings and its underlying recommendation does not reflect the opinion of TheStreet, Inc. or any of its contributors including Jim Cramer or Stephanie Link.

If you liked this article you might like

Week in Review: Trump Rally Fizzles but Stocks End 2016 With Big Gains

Post-Trump Rally Stalls as Dow Jones Slips Further From 20,000 Mark

Stocks Slump Continues With All S&P 500 Sectors in Negative Territory

Hacking Case Shows Mounting Risk for M&A Law Firms, Corporate Clients

Stocks Turn Negative, Prolonging Dow's Trek Toward 20,000